The GLP-1 drug category — Ozempic, Wegovy, Mounjaro, and the compounds behind them — has produced one of the fastest market expansions in pharmaceutical history. The forecasts keep being revised upward because the forecasts keep underestimating demand. Part of what makes this unusual is that the demand is coming from multiple directions simultaneously. There is the core … [Read more...] about The Obesity Drug Market Is Bigger Than Anyone Planned For